Highlights for the quarter:
-
Entered into a Strategic Collaboration with Imugene to combine Imugene’s onCARlytics platform and Arovella’s iNKT cell therapy platform in preclinical trials
-
Appointed Mr Gary Phillips as a Non-Executive Director
-
Completed a strategic review of the Company’s operations; decision to close the Perth R&D Facility.
For more information, download the attached PDF.
Download this document
